El EBITDA de Abbott India Limited es ₨10.524B
El EBITDA es la ganancia de una compañía antes de intereses, impuestos, depreciación y amortización y es una medida contable calculada usando las ganancias netas de la compañía, antes de que se resten los gastos de interés, los impuestos, la depreciación y la amortización, como un proxy de la rentabilidad operativa actual de la compañía.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolic, central nervous system, pain management, nutritional supplements, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.